Skip to main content
. 2024 Jan 15;15:519. doi: 10.1038/s41467-024-44786-2

Fig. 2. Efficient and specific elimination of Vβ2+ malignant T cells in vivo by allogeneic CAR-Vβ2 T cells.

Fig. 2

a Schematic of the NSG mouse model used to assess in vivo Vβ2+ T lymphoma killing by mCAR-Vβ2 T cells. Illustrations were created with BioRender.com and Adobe Illustrator. b–d Analysis of NSG bone marrow (BM) 10 days post inoculation of Jurkat-TRBV20-1 cells and subsequent treatment with triple KO CD8 mCAR-Vβ2 T cells vs no-treatment control (NC). b Representative flow cytometry quantified in (c, d). c Vβ2+ Jurkat-TRBV20-1 cell count, and (d) mCAR-Vβ2 T cell count with (red) or without (black) mCAR-Vβ2 treatment. e–l Analysis of NSG mice carrying CD4+ T cells from a Vβ2+ PTCL patient 1 week post treatment with triple KO CD8 mCAR-Vβ2 T cells vs no-treatment control (NC). e Representative NSG spleen cell flow cytometry quantified in (f–h) showing Vβ2+ PTCL cells, Vβ2-negative normal T cells and CD8 mCAR-Vβ2. f Vβ2+ PTCL cell count, (g) Vβ2-negative normal CD4+ T cell count, and (h) mCAR-Vβ2 T cell count in spleen with (red) or without (black) mCAR-Vβ2 treatment. i Representative NSG BM flow cytometry quantified in (j–l) showing Vβ2+ PTCL cells, Vβ2-negative normal T cells and CD8 mCAR-Vβ2. j Vβ2+ CTCL cell count (k) Vβ2- normal CD4+ T cell count, and (l) mCAR-Vβ2 T cell count in BM with (red) or without (black) mCAR-Vβ2 treatment. c–l N = 3 mice per group. Data are presented as mean values +/− SEM. *p < 0.05 and **p < 0.01 by two-sided t-test. Source data and exact p-values are provided as a Source Data file.